Sirio Pharma released its performance report for the first half of 2023. Sirio Pharma achieved an operating income of RMB 1.545 billion yuan (USD $210 million), with a year-on-year growth of 39%. It’s worth noting that its overseas business generated sales revenue of RMB 747 million yuan (USD $102 million), marking a significant year-on-year growth of 71.82%.
In January 2023, Sirio Pharma announced the completion of its acquisition of Best Formulation. Following the merger, the company’s operations in the Americas region saw a remarkable year-on-year growth of 101.7%. In April of this year, Sirio Pharma’s cross-border bonded factory in the Zhuhai-Macao Cross-Border Zone was officially launched, aiming to leverage the international industrial chain cooperation and serve as a hub for cross-border trade. (Source: shuzhengkangxun)
Sign Up to Receive China Updates Weekly Newsletter for FREE, HERE
Visit HPA-China’s Information Hub, HERE